Így működik a koronavírus elleni vakcina

hagyományos alapra épülő vakcina viszont egy elölt, gyengített, ám teljes vírust a virus nem él, valamit tudnak ezek, ha egy nem élőt megtudnak gyilkolni

Sorra jönnek a nyugati vakcinák, most épp 120 ezer adag Pfizer. Orbán valahogy mégsincs ott a szállítmányok érkezésekor, nem beszél róla, nincs Facebook-videó. Persze ha jön a kínai vakcina, akkor ott áll a reptéren, pöffeszkedik és ömlik a propaganda. Vajon miért? Azt hiszem a válasz egyszerű: Orbánt nem az oltás érdekli, hanem a saját érdekei, hogy ezredjére is elmondhassa hazugságait, hogy az Unió nem segít, bezzeg a kelet igen.

erre válaszóljanak.... 1. Following intramuscular injection, it must be expected that the gene-based vaccines will reach the bloodstream and disseminate throughout the body. We request evidence that this possibility was excluded in preclinical animal models with all three vaccines prior to their approval for use in humans by the EMA. 2. If such evidence is not available, it must be expected that the vaccines will remain entrapped in the circulation and be taken up by endothelial cells. There is reason to assume that this will happen particularly at sites of slow blood flow, i.e. in small vessels and capillaries. We request evidence that this probability was excluded in preclinical animal models with all three vaccines prior to their approval for use in humans by the EMA. 3. If such evidence is not available, it must be expected that during expression of the vaccines nucleic acids, peptides derived from the spike protein will be presented via the MHC I pathway at the luminal surface of the cells. Many healthy individuals have CD8-lymphocytes that recognize such peptides, which may be due to prior COVID infection, but also to cross-reactions with other types of Coronavirus. We must assume that these lymphocytes will mount an attack on the respective cells. We request evidence that this probability was excluded in preclinical animal models with all three vaccines prior to their approval for use in humans by the EMA. 4. If such evidence is not available, it must be expected that endothelial damage with subsequent triggering of blood coagulation via platelet activation will ensue at countless sites throughout the body. We request evidence that this probability was excluded in preclinical animal models with all three vaccines prior to their approval for use in humans by the EMA. 5. If such evidence is not available, it must be expected that this will lead to a drop in platelet counts, appearance of D-dimers in the blood, and to myriad ischaemic lesions throughout the body including in the brain, spinal cord and heart. Bleeding disorders might occur in the wake of this novel type of DIC-syndrome including, amongst other possibilities, profuse bleedings and haemorrhagic stroke. We request evidence that all these possibilities were excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA. 6. The SARS-CoV-2 spike protein binds to the ACE2 receptor on platelets, which results in their activation. Thrombocytopenia has been reported in severe cases of SARS-CoV-2 infection. Thrombocytopenia has also been reported in vaccinated individuals. We request evidence that the potential danger of platelet activation that would also lead to disseminated intravascular coagulation (DIC) was excluded with all three vaccines prior to their approval for use in humans by the EMA.

TUDTA? Így működik a védettségi igazolvány: https://www.youtube.com/watch?v=z8xyxvVFm7g